Related Experiment Videos
Helodermin and islet hormone release in isolated rat pancreas
1Department of Internal Medicine, Phillipps-University of Marburg, FRG.
Summary
Helodermin, a peptide hormone, significantly impacts pancreatic hormone secretion. It dose-dependently stimulates somatostatin and second-phase glucagon release, while inhibiting first-phase glucagon secretion.
Area of Science:
- Endocrinology
- Pancreatic Physiology
- Peptide Hormone Research
Background:
- Helodermin is a novel peptide belonging to the VIP/secretin/glucagon family.
- Understanding its effects on pancreatic islet hormone secretion is crucial for metabolic research.
Purpose of the Study:
- To investigate the effects of helodermin on glucose- and arginine-stimulated insulin, glucagon, and somatostatin secretion.
- To determine the dose-dependent responses of pancreatic hormones to helodermin.
Main Methods:
- Isolated perfused rat pancreas model used.
- Stimulation of hormone secretion induced by glucose (10 mmol/L) and arginine (10 mmol/L).
- Concentrations of helodermin tested: 1, 10, and 100 pmol/L.
Main Results:
- Helodermin significantly stimulated somatostatin release in a dose-dependent manner during both secretion phases.
- A biphasic effect on glucagon secretion was observed: inhibition in the first phase and stimulation in the second phase.
- Helodermin exhibited weak, dose-dependent stimulatory effects on insulin secretion, with maximal effects at 10 pmol/L.
Conclusions:
- Helodermin modulates pancreatic islet hormone secretion, notably stimulating somatostatin and influencing glucagon release.
- The peptide shows potential in regulating pancreatic endocrine function, warranting further investigation.
- Helodermin's distinct effects on different islet hormones highlight its complex role in glucose homeostasis.